dyer semaglutide Compounded Semaglutide and Tirzepatide vials now

Discover the impressive weight loss outcomes and learn which option might be best for you

CagriSema combo cut body weight by 20% in REDEFINE 1, outperforming placebo and single agents in adults with obesity.

This product is sold strictly for in-vitro research and laboratory use only

Five clinical trials in type 2-diabetic subjects (SURPASS 15) have shown that tirzepatide at 515 mg per week reduces both HbA1c (1.24 to 2.58%) and body weight (5.411.7 kg) by amounts unprecedented for a single agent

This investigational drug is distinctive in targeting GIP, GLP-1, and glucagon receptors, a novel approach compared to existing obesity treatments